Duchesnay has acquired exclusive rights from Shionogi Inc. to market and distribute Osphena (ospemifene) in the United States and Canada.
"We are very pleased to be continuing the excellent work done by Shionogi with Osphena in the U.S. and look forward to introducing this new product in Canada as soon as possible to help the thousands of women suffering from dyspareunia," Éric Gervais, executive vice president of Duchesnay, said in a press release.
Dyspareunia is a disorder that, when moderate to severe, can lead to painful intercourse for women. It is a symptom of vulvar and vaginal atrophy (VVA) due to menopause. An estimated 50 percent of postmenopausal women have VVA symptoms, and 40 percent of these women also suffer from dyspareunia.
"Shionogi feels that Duchesnay is the ideal partner to maximize the value of Osphena because of its track record of success, sole focus on women's health and commitment to improving the health of women,” Dr. Isao Teshirogi, president and CEO of Shionogi & Co. Ltd, said in the release. “We are also very happy to embark in this new endeavor with Duchesnay to bring Osphena to patients in Canada.”
